Introduction
Methods
Study design, population and setting
Real world data: the Valencia healthcare integrated databases (VID)
Study cohorts
Endpoints related to HZ
Statistical analysis
Ethical considerations
Results
Study population
Characteristics | Population (n = 4,382,590) | IC (n = 578,873) | HIV (n = 13,612) | HSCT (n = 1779) | SOT (n = 18,456) | NEOPLASIAS (n = 306,125) | SON (n = 257,271) | HAEMATOL. NEOP. (n = 55,082) | RA (n = 39,962) |
---|---|---|---|---|---|---|---|---|---|
Gender N(%) | |||||||||
Man | 2,145,709 (48.96) | 279,122 (48.22) | 9716 (71.38) | 1030 (57.90) | 10,417 (56.44) | 159,526 (52.11) | 137,305 (53.37) | 26,063 (47.32) | 12,722 (31.84) |
Woman | 2,236,881 (51.04) | 299,751 (51.78) | 3896 (28.62) | 749 (42.10) | 8039 (43.56) | 146,599 (47.89) | 119,966 (46.63) | 29,019 (52.68) | 27,240 (68.16) |
Age (years) N | |||||||||
18–29 | 1,019,731 | 62,407 | 1193 | 160 | 1261 | 11,711 | 3042 | 8559 | 2186 |
30–39 | 1,274,301 | 87,590 | 4064 | 276 | 2741 | 19,795 | 9707 | 9829 | 4249 |
40–49 | 1,243,357 | 110,019 | 7630 | 437 | 4210 | 35,539 | 25,715 | 10,120 | 7587 |
50–59 | 1,004,914 | 123,921 | 4124 | 628 | 5018 | 58,593 | 49,518 | 10,063 | 10,756 |
60–69 | 817,757 | 138,911 | 1147 | 602 | 5347 | 86,499 | 76,706 | 11,562 | 11,826 |
70–79 | 677,388 | 140,359 | 476 | 131 | 4340 | 100,993 | 91,240 | 12,276 | 11,391 |
≥ 80 | 441,778 | 98,905 | 218 | 14 | 2209 | 77,824 | 70,907 | 8962 | 7033 |
Calendar year N | |||||||||
2009 | 4,148,325 | 264,163 | 7946 | 602 | 9622 | 129,941 | 109,293 | 21,987 | 22,283 |
2010 | 4,088,345 | 307,912 | 8555 | 747 | 10,680 | 148,998 | 123,615 | 27,113 | 24,819 |
2011 | 4,048,771 | 349,165 | 9161 | 879 | 11,849 | 166,335 | 136,548 | 31,943 | 27,275 |
2012 | 4,028,926 | 395,378 | 9822 | 1014 | 13,416 | 187,925 | 153,776 | 36,770 | 30,207 |
2013 | 3,924,744 | 444,279 | 10,888 | 1166 | 14,907 | 211,033 | 171,910 | 42,451 | 33,376 |
2014 | 3,913,476 | 494,693 | 11,810 | 1312 | 16,165 | 234,675 | 191,360 | 47,310 | 36,401 |
Nationality N (%) | *N = 4,212,716 | *N = 563,730 | *N = 13,136 | *N = 1703 | *N = 17,993 | *N = 293,839 | *N = 246,025 | *N = 48,919 | *N = 39,245 |
Spanish | 3,716,485 (88.22) | 523,698 (92.90) | 11,823 (90) | 1618 (95.01) | 16,996 (94.46) | 275,929 (93.90) | 232,726 (94.59) | 48,919 (97.36) | 35,997 (91.72) |
Other | 496,231 (11.78) | 40,032 (7.10) | 1313 10) | 85 (4.99) | 997 (5.54) | 17,910 (6.10) | 13,299 (5.41) | 1329 (2.64) | 3248 (8.28) |
Rural N (%) | *N = 4,380,289 | *N = 578,747 | *N = 13,602 | *N = 1779 | *N = 18,450 | *N = 306,032 | *N = 257,181 | *N = 55,078 | *N = 39,958 |
Yes | 109,358 (2.50) | 14,906 (2.58) | 216 (1.59) | 46 (2.59) | 417 (2.26) | 8631 (2.82) | 7353 (2.86) | 1464 (2.66) | 1145 (2.87) |
No | 4,270,931 (97.50) | 563,841 (97.42) | 13,386 (98.41) | 1733 (97.41) | 18,033 (97.74) | 297,401 (97.18) | 249,828 (97.14) | 53,614 (97.34) | 38,813 (97.13) |
Social exclusion N (%) | *N = 4,021,588 | *N = 535,996 | *N = 12,492 | *N = 1565 | *N = 17,260 | *N = 271,137 | *N = 225,205 | *N = 51,202 | *N = 37,974 |
Yes | 629,179 (15.65) | 67,878 (12.66) | 3825 (69.38) | 157 (10.03) | 1894 (10.97) | 34,988 (8.72) | 16,989 (7.54) | 6870 (13.42) | 4594 (12.10) |
No | 3,392,409 (84.35) | 468,118 (87.34) | 8667 (30.62) | 1408 (89.97) | 15,359 (89.03) | 247,491 (91.28) | 208,216 (92.46) | 44,332 (86.58) | 33,380 (87.90) |
Characteristics | SLE (n = 4878) | IBD (n = 28,700) | PSORIASIS (n = 139,843) | MS (n = 4747) | AT (n = 9205) | DIABETES (n = 491,210) | COPD (n = 222,902) | HF (n = 139,706) | CKD (n = 149,805) |
Gender N(%) | |||||||||
Man | 769 (15.76) | 14,599 (50.87) | 69,058 (49.38) | 1478 (31.14) | 1017 (11.05) | 258,320 (52.59) | 147,456 (66.15) | 62,781 (44.92) | 82,034 (54.76) |
Woman | 4109 (84.24) | 14,101 (49.13) | 70,785 (50.62) | 3269 (68.86) | 8188 (88.95) | 232,890 (47.41) | 75,446 (33.85) | 76,925 (55.06) | 67,771 (45.24) |
Age (years) N | |||||||||
18–29 | 528 | 4191 | 33,887 | 659 | 1178 | 8673 | 3628 | 374 | 2471 |
30–39 | 1272 | 7480 | 36,959 | 1661 | 2337 | 20,838 | 7742 | 903 | 4722 |
40–49 | 1702 | 8336 | 35,032 | 1890 | 2755 | 53,081 | 19,076 | 2933 | 7732 |
50–59 | 1421 | 6678 | 30,709 | 1344 | 2751 | 112,581 | 39,360 | 8258 | 14,114 |
60–69 | 952 | 5512 | 25,260 | 822 | 2011 | 172,642 | 65,680 | 20,223 | 27,378 |
70–79 | 650 | 4800 | 17,493 | 384 | 1085 | 193,949 | 87,338 | 49,731 | 52,166 |
≥ 80 | 305 | 2658 | 8088 | 113 | 446 | 129,895 | 72,965 | 83,660 | 71,404 |
Calendar year N | |||||||||
2009 | 2572 | 15,898 | 62,492 | 3047 | 3720 | 347,604 | 126,850 | 58,503 | 53,640 |
2010 | 2973 | 17,772 | 77,137 | 3349 | 4722 | 365,745 | 136,093 | 65,374 | 61,943 |
2011 | 3333 | 19,513 | 91,288 | 3639 | 6021 | 378,199 | 143,759 | 70,843 | 71,205 |
2012 | 3795 | 21,777 | 105,590 | 3896 | 6980 | 393,050 | 159,700 | 77,206 | 80,269 |
2013 | 4203 | 24,326 | 120,067 | 4156 | 7992 | 404,193 | 165,847 | 81,202 | 88,993 |
2014 | 4587 | 26,890 | 134,664 | 4446 | 9002 | 413,834 | 172,506 | 86,214 | 98,296 |
Nationality N (%) | *N = 4828 | *N = 28,347 | *N = 138,860 | *N = 4678 | *N = 9172 | *N = 474,241 | *N = 213,515 | *N = 131,310 | *N = 142,213 |
Spanish | 4488 (92.96) | 26,659 (94.05) | 127,492 (91.81) | 4353 (93.05) | 8673 (94.56) | 449,835 (94.85) | 203,216 (95.18) | 126,428 (96.28) | 135,333 (95.16) |
Other | 340 (7.04) | 1688 (5.95) | 11,368 (8.19) | 325 (6.95) | 499 (5.44) | 24,406 (5.15) | 10,299 (4.82) | 4882 (3.72) | 6880 (4.84) |
Rural N (%) | *N = 4878 | *N = 28,694 | *N = 139,836 | *N = 4745 | *N = 9204 | *N = 491,069 | *N = 222,830 | *N = 139,639 | *N = 149,744 |
Yes | 91 (1.87) | 28,077 (97.85) | 3017 (2.16) | 112 (2.36) | 520 (5.65) | 13,830 (2.82) | 6758 (3.03) | 4938 (3.54) | 4136 (2.76) |
No | 4787 (98.13) | 617 (2.15) | 136,819 (97.84) | 4633 (97.64) | 8684 (94.35) | 477,239 (97.18) | 216,072 (96.97) | 134,701 (96.46) | 145,608 (97.24) |
Social exclusion N (%) | *N = 4718 | *N = 27,671 | *N = 136,789 | *N = 4562 | *N = 9108 | *N = 447,728 | *N = 197,306 | *N = 114,628 | *N = 126,804 |
Yes | 3894 (82.53) | 23,858 (86.22) | 23,130 (16.91) | 718 (15.74) | 1546 (16.97) | 44,835 (10.01) | 18,311 (9.28) | 4776 (4.17) | 7732 (6.10) |
No | 824 (17.47) | 3813 (13.78) | 113,659 (83.09) | 3844 (84.26) | 7562 (83.03) | 402,893 (89.99) | 178,995 (90.72) | 109,852 (95.83) | 119,072 (93.90) |
HZ incidence rates
IC condition | Incidence rate of HZ per 1000 PY (95% CI) | |||||||
---|---|---|---|---|---|---|---|---|
18–29 | 30–39 | 40–49 | 50–59 | 60–69 | 70–79 | ≥ 80 | Overall | |
Population | 2.32 (2.27–2.37) | 2.46 (2.42–2.51) | 2.93 (2.88–2.98) | 5.88 (5.80–5.96) | 8.63 (8.53–8.74) | 9.82 (9.69–9.95) | 10 (9.83–10.16) | 5.02 (4.99–5.04) |
IC-free cohort | 2.26 (2.21–2.31) | 2.36 (2.32–2.41) | 2.75 (2.70–2.80) | 5.52 (5.44–5.61) | 8.12 (8.01–8.23) | 9.29 (9.15–9.43) | 9.54 (9.36–9.71) | 4.64 (4.61–4.67) |
IC-cohort | 3.61 (3.33–3.91) | 4.28 (4.02–4.54) | 5.52 (5.26–5.79) | 9.55 (9.22–9.90) | 12.42 (12.05–12.80) | 12.93 (12.54–13.33) | 12.69 (12.21–13.29) | 9.15 (9.02–9.29) |
HSCT | 42.37 (21.89–74.02) | 38.94 (24.11–59.53) | 50.13 (35.81–68.26) | 69.24 (54.08–87.33) | 61.82 (47.5–79.1) | 51.99 (24.93–95.61) | 0 | 56.07 (48.86–64.04) |
SOT | 6 (3.61–9.37) | 6.23 (4.58–8.29) | 7.31 (5.83–9.05) | 14.89 (12.87–17.14) | 17.02 (14.93–19.32) | 14.21 (12.06–16.62) | 17.26 (13.83–21.29) | 12.65 (11.8–13.54) |
HN | 4.96 (4.1–5.94) | 4.53 (3.77–5.41) | 5.86 (4.97–6.87) | 13.95 (12.5–15.52) | 18.03 (16.46–19.7) | 20.06 (18.37–21.85) | 18.44 (16.46–20.6) | 11.99 (11.48–12.52) |
SON | 3.87 (2.59–5.56) | 4.94 (4.1–5.9) | 5.84 (5.25–6.49) | 10.24 (9.66–10.85) | 12.27 (11.76–12.80) | 12.12 (11.64–12.62) | 12 (11.43–12.59) | 10.97 (10.73–11.22) |
NEOPLASIAS | 4.64 (3.92–5.45) | 4.71 (4.14–5.33) | 5.86 (5.36–6.40) | 10.70 (10.16–11.26) | 12.86 (12.40–13.40) | 12.91 (12.43–13.39) | 12.53 (11.98–13.11) | 11.01 (10.79–11.23) |
HIV | 11.9 (8.08–16.89) | 12.34 (10.28–14.7) | 13.44 (11.96–15.06) | 12.8 (10.65–15.27) | 13.99 (9.9–19.2) | 11.38 (5.68–20.36) | 3.87 (0.1–21.56) | 12.94 (11.95–13.99) |
AUTOIMMUNE | 3.35 (3.05–3.67) | 3.9 (3.62–4.2) | 4.7 (4.4–5.01) | 8.97 (8.54–9.42) | 12.41 (11.87–12.98) | 13.98 (13.32–14.66) | 13.34 (12.45–14.27) | 7.88 (7.71–8.05) |
RA | 4.19 (2.74–6.14) | 5.34 (4.1–6.83) | 6.03 (5.04–7.16) | 10.22 (9.11–11.42) | 13.88 (12.65–15.2) | 14.3 (13–15.7) | 13.71 (12.05–15.53) | 11.05 (10.52–11.59) |
SLE | 9.76 (5.33–16.37) | 8.62 (5.93–12.1) | 8.37 (6.01–11.36) | 17.2 (13.27–21.92) | 20.37 (15.07–26.94) | 21.8 (14.81–30.94) | 19.63 (10.73–32.93) | 13.36 (11.75–15.14) |
IBD | 4.83 (3.66–6.25) | 4.6 (3.78–5.56) | 5.16 (4.31–6.12) | 9.65 (8.3–11.16) | 13.4 (11.59–15.4) | 12.97 (11.01–15.18) | 16.21 (13.21–19.67) | 8.29 (7.77–8.84) |
PSORIASIS | 2.97 (2.63–3.34) | 3.37 (3.03–3.74) | 3.74 (3.37–4.14) | 7.55 (6.98–8.16) | 10.39 (9.65–11.16) | 12.4 (11.41–13.44) | 11.11 (9.72–12.64) | 6.13 (5.92–6.34) |
MS | 5.48 (2.51–10.4) | 4.39 (2.75–6.64) | 4.13 (2.67–6.09) | 7.22 (4.87–10.31) | 12.34 (8.33–17.62) | 10.96 (5.47–19.62) | 12.15 (2.51–35.51) | 6.33 (5.29–7.51) |
AT | 1.35 (0.37–3.47) | 2.07 (1.1–3.55) | 4.21 (2.88–5.94) | 10 (7.9–12.5) | 11.06 (8.42–14.27) | 13.56 (9.64–18.54) | 17.97 (10.82–28.06) | 7.19 (6.31–8.15) |
aHZ RR (95% CrI) | bHZ-Complications RR (95% CrI) | bHZ-Recurrence RR (95% CrI) | ||
---|---|---|---|---|
IC | IC-free | 1 | 1 | 1 |
IC | 1.51 (1.48–1.54) | 2.37 (2.01–2.8) | 1.25 (1.19–1.31) | |
SEX | Man | 1 | 1 | 1 |
Woman | 1.33 (1.31–1.35) | 1.15 (0.98–1.35) | 1.19 (1.14–1.24) | |
AGE | 18–29 | 1 | 1 | 1 |
30–39 | 1.06 (1.02–1.09) | 5.62 (2.63–11.99) | 1.08 (0.95–1.23) | |
40–49 | 1.24 (1.2–1.29) | 9.71 (4.9–19.24) | 1.14 (1.01–1.28) | |
50–59 | 2.42 (2.35–2.5) | 7.74 (3.95–15.16) | 1.21 (1.08–1.36) | |
60–69 | 3.43 (3.32–3.54) | 12.3 (6.84–22.1) | 1.52 (1.36–1.7) | |
70–79 | 3.72 (3.61–3.85) | 26.14 (14.72–46.44) | 1.9 (1.7–2.12) | |
≥ 80 | 3.57 (3.45–3.7) | 39.72 (22.5–70.12) | 2.14 (1.91–2.4) | |
COMORBIDITIES | ||||
COPD | NO-COPD | 1 | 1 | 1 |
COPD | 1.36 (1.32–1.4) | 2.54 (2.11–3.06) | 1.26 (1.17–1.35) | |
DIABETES | NO-DIABETES | 1 | 1 | 1 |
DIABETES | 1.12 (1.09–1.14) | 1.07 (0.89–1.28) | 1.05 (1–1.11) | |
HF | NO-HF | 1 | 1 | 1 |
HF | 1.16 (1.11–1.21) | 2.07 (1.68–2.55) | 1.63 (1.39–1.9) | |
CKD | NO-CKD | 1 | 1 | 1 |
CKD | 1.18 (1.13–1.23) | 1.63 (1.31–2.03) | 1.2 (1.09–1.33) |
Incidence rates of HZ - related complications
IC condition | Incidence rate of HZ complications per 100,000 PY (95% CI) | |||||||
---|---|---|---|---|---|---|---|---|
18–29 | 30–39 | 40–49 | 50–59 | 60–69 | 70–79 | ≥ 80 | Overall | |
Population | 0.35 (0.18–0.59) | 0.75 (0.53–1.04) | 1.09 (0.81–1.44) | 1.34 (0.99–1.77) | 4.34 (3.63–5.15) | 10.89 (9.6–12.31) | 21.35 (19.08–23.81) | 3.63 (3.39–3.88) |
IC-free cohort | 0.33 (0.17–0.58) | 0.49 (0.3–0.73) | 0.47 (0.29–0.73) | 0.78 (0.51–1.15) | 2.95 (2.33–3.68) | 8.48 (7.25–9.85) | 18.78 (16.49–21.3) | 2.64 (2.42–2.86) |
IC cohort | 0.58 (0.01–3.21) | 5.55 (3.04–9.32) | 9.74 (6.57–13.9) | 6.91 (4.38–10.37) | 14.3 (10.71–18.7) | 24.76 (19.83–30.54) | 36.12 (28.68–44.89) | 14.36 (12.75–16.11) |
HSCT | 310.46 (7.86–1729.79) | 161.25 (4.08–898.45) | 759.63 (305.41–1565.13) | 161.39 (19.55–583) | 232.54 (47.95–679.57) | 0 (0–1492.1) | 0 (0–25,474.82) | 300.77 (164.43–504.63) |
SOT | 0 (0–112.66) | 38.5 (7.94–112.52) | 41.92 (13.61–97.83) | 35.98 (11.68–83.97) | 90.74 (49.61–152.25) | 50.33 (18.47–109.55) | 36.08 (4.37–130.34) | 50.16 (34.94–69.76) |
HN | 4.13 (0.1–23) | 10.68 (2.2–31.22) | 40.77 (20.35–72.95) | 15.49 (4.22–39.65) | 47.43 (25.93–79.58) | 51.98 (29.09–85.73) | 52.86 (25.35–97.22) | 31.8 (24.15–41.11) |
SON | 13.14 (0.33–73.22) | 8 (0.97–28.91) | 9.69 (3.56–21.1) | 6.69 (2.89–13.19) | 11.9 (7.46–18.01) | 22.86 (16.86–30.31) | 36.96 (27.84–48.1) | 18.74 (15.79–22.09) |
NEOPLASIAS | 3.1 (0.08–17.3) | 7.39 (2.01–18.91) | 16.95 (9.49–27.96) | 7.66 (3.82–13.71) | 14.68 (9.97–20.83) | 25.14 (19.14–32.43) | 38.84 (29.91–49.6) | 19.91 (17.15–23) |
HIV | 0 (0–131.63) | 54.1 (19.85–117.76) | 37.1 (16.96–70.43) | 37.36 (10.18–95.65) | 98.64 (20.34–288.25) | 95.01 (2.41–529.36) | 0 (0–1269.77) | 43.2 (27.38–64.82) |
AUTOIMMUNE | 0.71 (0.02–3.96) | 3.15 (1.16–6.86) | 7.91 (4.52–12.84) | 4.25 (1.83–8.37) | 15.32 (10.01–22.45) | 25.27 (17.39–35.48) | 30.81 (19.07–47.09) | 10.18 (8.37–12.26) |
RA | 0 (0–58.05) | 8.28 (0.21–46.11) | 4.5 (0.11–25.08) | 3.15 (0.08–17.56) | 11.08 (3.02–28.37) | 27.05 (12.37–51.36) | 40.7 (17.57–80.2) | 14.87 (9.53–22.12) |
SLE | 0 (0–244.45) | 25.12 (0.64–139.94) | 38.74 (4.69–139.92) | 24.55 (0.62–136.78) | 0 (0–136.77) | 61.59 (1.56–343.18) | 0 (0–461.25) | 25.19 (8.18–58.79) |
IBD | 0 (0–30.57) | 4.17 (0.11–23.23) | 3.84 (0.1–21.39) | 0 (0–18.68) | 18.94 (3.91–55.34) | 15.59 (1.89–56.3) | 29.53 (3.58–106.69) | 7.67 (3.51–14.57) |
PSORIASIS | 0 (0–3.86) | 0 (0–3.42) | 0.99 (0.03–5.52) | 2.27 (0.27–8.19) | 6.63 (2.15–15.48) | 7.88 (2.15–20.17) | 35.83 (15.47–70.6) | 3.7 (2.26–5.71) |
MS | 0 (0–220.87) | 0 (0–71.54) | 0 (0–59.58) | 0 (0–85.36) | 38.62 (0.98–215.15) | 0 (0–344.05) | 0 (0–1436.88) | 4.7 (0.12–26.21) |
AT | 0 (0–123.35) | 15.73 (0.4–87.64) | 0 (0–47.47) | 0 (0–46.07) | 0 (0–64.98) | 0 (0–117.91) | 0 (0–322.51) | 2.85 (0.07–15.89) |
Recurrence of HZ
IC condition | Recurrence rate of HZ per 100 PY (95% CI) | |||||||
---|---|---|---|---|---|---|---|---|
18–29 | 30–39 | 40–49 | 50–59 | 60–69 | 70–79 | ≥ 80 | Overall | |
Population | 0.99 (0.9–1.09) | 1.13 (1.05–1.21) | 1.19 (1.11–1.27) | 1.31 (1.25–1.38) | 1.7 (1.63–1.77) | 2.2 (2.12–2.28) | 2.71 (2.6–2.83) | 1.66 (1.63–1.69) |
IC-free cohort | 0.93 (0.84–1.02) | 1.08 (1–1.16) | 1.1 (1.02–1.18) | 1.23 (1.16–1.3) | 1.62 (1.55–1.7) | 2.09 (2–2.18) | 2.62 (2.49–2.75) | 1.56 (1.53–1.59) |
IC cohort | 1.88 (1.44–2.42) | 1.63 (1.32–1.99) | 1.87 (1.6–2.18) | 1.81 (1.61–2.03) | 2.08 (1.9–2.27) | 2.69 (2.48–2.92) | 3.13 (2.84–3.44) | 2.28 (2.18–2.38) |
HSCT | 7.38 (1.52–21.56) | 2.33 (0.28–8.4) | 5.05 (2.18–9.95) | 5.39 (2.87–9.22) | 5.48 (3.07–9.04) | 13.84 (4.49–32.31) | 5.5 (4.03–7.34) | |
SOT | 2.83 (0.58–8.26) | 2.87 (1.15–5.92) | 3.12 (1.7–5.23) | 2.94 (1.94–4.28) | 2.62 (1.8–3.68) | 3.55 (2.38–5.1) | 3.27 (1.74–5.59) | 3.01 (2.5–3.58) |
HN | 3.32 (1.93–5.31) | 1.89 (1.01–3.23) | 2.04 (1.21–3.23) | 3.27 (2.45–4.27) | 3.08 (2.42–3.85) | 4.16 (3.39–5.04) | 4.03 (3.08–5.18) | 3.35 (3.01–3.73) |
SON | 1.88 (0.39–5.5) | 2.32 (1.27–3.89) | 1.82 (1.23–2.58) | 1.82 (1.49–2.2) | 2.04 (1.78–2.33) | 2.46 (2.19–2.75) | 3.18 (2.81–3.58) | 2.37 (2.22–2.53) |
NEOPLASIAS | 2.93 (1.79–4.52) | 1.99 (1.3–2.91) | 1.91 (1.41–2.52) | 2 (1.69–2.36) | 2.17 (1.92–2.43) | 2.67 (2.42–2.95) | 3.24 (2.89–3.62) | 2.5 (2.36–2.64) |
HIV | 3.53 (1.3–7.69) | 1.99 (1.11–3.28) | 3.01 (2.22–3.99) | 3.96 (2.61–5.76) | 4.76 (2.38–8.52) | 8.39 (2.73–19.59) | 0 (0–48.47) | 3.2 (2.63–3.85) |
AUTOIMMUNE | 1.65 (1.19–2.24) | 1.48 (1.13–1.9) | 1.66 (1.33–2.05) | 1.62 (1.37–1.91) | 2.1 (1.84–2.4) | 2.84 (2.5–3.21) | 3.1 (2.6–3.66) | 2.12 (1.98–2.26) |
RA | 1.57 (0.19–5.67) | 1.49 (0.48–3.47) | 2.06 (1.18–3.35) | 1.68 (1.12–2.43) | 2.58 (2–3.28) | 2.6 (1.99–3.34) | 3.33 (2.42–4.48) | 2.43 (2.12–2.77) |
SLE | 0 (0–5.28) | 2.73 (0.89–6.37) | 3.21 (1.39–6.33) | 2.97 (1.42–5.46) | 3.23 (1.48–6.13) | 1.3 (0.16–4.69) | 4.01 (0.83–11.71) | 2.75 (1.93–3.79) |
IBD | 1.95 (0.71–4.24) | 2.19 (1.16–3.74) | 1.58 (0.82–2.77) | 1.65 (0.94–2.68) | 2.5 (1.64–3.63) | 3.49 (2.3–5.07) | 4.73 (2.97–7.16) | 2.48 (2.06–2.96) |
PSORIASIS | 1.64 (1.06–2.42) | 1.36 (0.9–1.96) | 1.28 (0.85–1.85) | 1.46 (1.1–1.9) | 1.71 (1.34–2.16) | 2.39 (1.89–2.98) | 2.88 (2.04–3.96) | 1.77 (1.58–1.97) |
MS | 0 (0–9.86) | 1.59 (0.19–5.73) | 4.08 (1.5–8.87) | 0 (0–2.08) | 2.59 (0.71–6.64) | 2.89 (0.35–10.44) | 0 (0–37.33) | 1.94 (1.06–3.26) |
AT | 0 (0–9.6) | 2.34 (0.28–8.45) | 0.57 (0.01–3.16) | 1.75 (0.71–3.61) | 1.8 (0.66–3.92) | 2.5 (0.81–5.84) | 2.97 (0.61–8.69) | 1.8 (1.15–2.68) |
Healthcare resources utilization
IC | |
---|---|
PC visits for HZ | RR (95% CI) |
1.02 (1.01–1.03) | |
Specialist visits for HZ | RR (95% CI) |
1.66 (1.57–1.76) | |
Hospitalizationsa | OR (95% CI) |
2.93 (2.62–3.27) | |
Length of hospital stay | Mean ratio (95% CI) |
1.12 (1.02–1.23) | |
Sick leave | Mean ratio (95% CI) |
1.18 (1.03–1.35) | |
Medication for HZ | RR (95% CI) |
1.2 (1.17–1.22) |